Ankyra in the News
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Press Releases
Ankyra Therapeutics Presents Preliminary Phase 1 Canine Clinical Data Evaluating cANK-101 to Treat Advanced Malignant Melanoma in Dogs
First-in-class anchored IL-12 immunotherapy increases immune cell infiltration into tumors while decreasing systemic toxicity Human ANK-101, an IL-12- based anchored immunotherapy, will begin Phase 1 clinical studies in 2024 CAMBRIDGE, MA – October 14, 2023...
Ankyra Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ANK-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
ANK-101 is a novel first-in-class anchored IL-12 immunotherapy designed for limited intratumoral delivery to increase immune cell infiltration into tumors, with potential to improve outcomes of patients treated with immune checkpoint inhibitors CAMBRIDGE, Mass. –...
Ankyra Therapeutics Appoints Robert V. Tighe, an accomplished industry veteran, as Chief Scientific Officer
August 7, 2023, CAMBRIDGE, MA – Ankyra Therapeutics, a pre-clinical biotechnology company developing targeted immune potentiating agents for the treatment of cancer, today announced the appointment of Robert V. Tighe., as chief scientific officer. He joined the team...
Ankyra Therapeutics Presents Preliminary Canine Clinical Data with cANK-101 Supporting Therapeutic Potential of Anchored Immunotherapy
Preliminary data of anchored canine IL-12 (cANK-101) in dogs with malignant melanoma demonstrates tolerable safety and early signs of biologic activity. Human ANK-101 is an IL-12- based anchored immunotherapy with IND submission planned for late 2023 BOSTON, MA, April...
Ankyra Therapeutics Appoints Experienced Financial Executive Stephen Gorgol as Chief Financial Officer
Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced the appointment of Stephen Gorgol as chief financial officer. Mr. Gorgol, a proven financial leader within the biotech industry, joins...
Ankyra Therapeutics Announces Collaboration to Evaluate ANK-101 in Early Clinical Trials Focused on Lung Cancer
Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that is has entered into a strategic collaboration with the Lung Cancer Initiative (LCI) at Johnson & Johnson*. The collaboration will...